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Mercedes Álvarez,†,§,∥ Fernando Albericio,†,§,⊥ and Miquel Coll*,†,‡
†Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12,
08028 Barcelona, Spain
‡Molecular Biology Institute of Barcelona (IBMBCSIC), Barcelona Science Park, Baldiri Reixac 10-12, 08028 Barcelona, Spain
§CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, Barcelona Science Park, 08028 Barcelona,
Spain
∥Laboratory of Organic Chemistry, Faculty of Pharmacy, University of Barcelona, 08028 Barcelona, Spain
⊥Department of Organic Chemistry, University of Barcelona, Martí i Franques̀ 1, 08028 Barcelona, Spain
*S Supporting Information
ABSTRACT: Human cytomegalovirus (HCMV) is an opportunistic pathogen causing a
variety of severe viral infections, including irreversible congenital disabilities. Nowadays,
HCMV infection is treated by inhibiting the viral DNA polymerase. However, DNA
polymerase inhibitors have several drawbacks. An alternative strategy is to use
compounds against the packaging machinery or terminase complex, which is essential
for viral replication. Our discovery that raltegravir (1), a human immunodeficiency virus
drug, inhibits the nuclease function of UL89, one of the protein subunits of the complex,
prompted us to further develop terminase inhibitors. On the basis of the structure of 1, a
library of diketoacid (α,γ-DKA and β,δ-DKA) derivatives were synthesized and tested for
UL89-C nuclease activity. The mode of action of α,γ-DKA derivatives on the UL89 active
site was elucidated by using X-ray crystallography, molecular docking, and in vitro
experiments. Our studies identified α,γ-DKA derivative 14 able to inhibit UL89 in vitro in
the low micromolar range, making 14 an optimal candidate for further development and
virus-infected cell assay.
■ INTRODUCTION
Human cytomegalovirus (HCMV), one of the eight known
human herpesviruses, is widespread with a high prevalence
throughout the human population.1 HCMV causes severe
diseases and life-threatening conditions in immune-compro-
mised individuals, such as acquired immunodeficiency syn-
drome, and organ transplant patients, neonates, and young
children.1 It is the leading congenital infection in developed
countries, causing a number of neural abnormalities including
hearing loss, mental retardation, and microcephalia. The drugs
licensed so far for the treatment of HCMV infection are the
antisense oligonucleotide fomivirsen and four viral DNA
polymerase inhibitors: ganciclovir (GCV), valganciclovir,
cidofovir (CDV), and foscarnet (FOS).2 There are several
disadvantages associated with the use of these drugs including
(i) poor bioavailability, (ii) serious side effects induced by
prolonged treatment, and (iii) emergence of resistant viral
strains.3 Development of drug resistance is associated with an
aggressive clinical course, organ dysfunction, and mortality.4
Several cases of multidrug resistance to GCV, CDV, and FOS
have been reported.5 Therefore, there is an urgent need for the
development of new drugs with a different mode of action, good
bioavailability, and a safer pharmacological profile. Novel classes
of antiviral compounds able to target viral entry, transcription,
protein synthesis and processing, genome replication, or
maturation have been identified.2,6−13 Among these, a
promising strategy is to block the HCMV terminase
machinery14 which mediates DNA binding, cleavage, and
packaging because these processes do not occur in mammalian
cells and therefore specific terminase inhibitors could have fewer
undesirable side effects.
HCMV replicates its genome as concatamers that are large
DNA molecules with several copies of the genome. Afterward,
these are cut into single unit-length genome and packaged inside
the capsids by the HCMV terminase machinery.15 HCMV
terminase is a protein complex composed of UL56, UL89, and
UL51 responsible for binding, cleavage, and translocation of
viral DNA inside the procapsids, respectively.15−17 The three-
dimensional (3D) structure of the nuclease domain of UL89 was
determined by X-ray crystallography,18 whereas the structures of
UL56 and UL51 are not elucidated yet.
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Letermovir, a 3,4-dihydro-quinazoline-4-yl-acetic acid deriv-
ative, a non-nucleoside inhibitor with a potent antiviral activity,
specific against the viral terminase subunit pUL56,19,20 has been
developed by AiCuris GmbH & Co KG and is currently in a
phase III clinical study.21 An alternative approach consists of
targeting UL89, another subunit of the terminase complex,
which contains two domains, the C-terminal region (UL89-C,
418-674), which has proved nuclease activity,16,18,22 and the N-
terminal part (UL89-N, 1-417), which has putative adenosine-
triphosphatase activity.23−25 UL89 inhibitors may be designed
to block the adenosine 5′-triphosphate (ATP) binding site on
the UL89-N region; amongst them, there are 2-bromo-5,6-





4766), which interact with the ATP binding site and induce
mutations on the UL89-N domain.15,26−32 However, in spite of
the efforts, none of them have reached the market.2,6,7 The
presence of the highly conserved ATP binding motif in many
different proteins could impede to obtain specific inhibitors for
the viral UL89-N.33
Another approach is focused on finding HCMV inhibitors
able to target the nuclease activity of UL89-C. The structure of
UL89-C, which is structurally related to the human
immunodeficiency virus (HIV) integrase,18 exhibits a central
eight-stranded mixed β-sheet, with parallel and antiparallel
strands, flanked on both sides by six α-helices. The nuclease
active site of UL89-C is located in a cleft formed by three loops
β2−β3, β5−α3, and α5−α6. Three acidic residues Asp463,
Asp651, and Glu534 chelate two Mn2+ ions, which are essential
for UL89-C DNA cleavage. An UL89-C nuclease inhibitor
should interact with the two Mn2+ ions and the amino acids
located in the loops to block DNA interaction and cleavage.
Most of the compounds against UL89-C tested so far are
divalent metal-sequestering inhibitors, such as 1-(3-chloro-4-
fluorobenzyl)-5-hydroxy-4-oxo-1,4-dihydropyridine-3-carbox-
ylic acid34 (Figure S1), an hydroxypyridonecarboxylic (HPC)
derivative, and 3-hydroxy-1-methyl-6-((4′-methyl-[1,1′-biphen-
yl]-4-yl)amino)dihydropyrimidine-2,4(1H,3H)-dione35 (Fig-
ure S1), a 3-hydroxypyrimidine-2,4-dione (HPD) derivative.
HPC and HPD compounds inhibit the nuclease activity of
UL89-C in the low micromolar range (IC50 = 2.2 and 1 μM,
respectively), HCMV replication, and infectious virus produc-
tion in cell culture.35 Therefore, there is a correlation between
blocking of pUL89 endonuclease activity and inhibition of
HCMV replication and viral genome cleavage. Recently, 2,7-
dihydroxy-4-(propan-2-yl)cyclohepta-2,4,6-trien-1-one (Figure
S1) with metal-chelating motifs was identified as an inhibitor of
pUL15C of herpes simplex viruses 1, a homologue of pUL89-
C.36 Crystallographic studies of 2,7-dihydroxy-4-(propan-2-
yl)cyclohepta-2,4,6-trien-1-one binding to the nuclease active
site of bacteriophage terminase gp2 nuclease domain revealed
that the interaction is mainly mediated by the two metal ions
(PDB code: 5C2F).37
Previous studies have reported the structure−activity relation-
ships (SARs) of UL89 inhibitors explained by molecular
docking simulation, using the apo form of UL89, without the
possibility to validate docking binding mode because there is no
UL89-inhibitor complex available. Clearly, it is important to
have an understanding of the interactions of UL89 inhibitors
with UL89 and offer detailed information to drive a target-based
drug discovery program against HCMV. We have focused our
efforts on elucidating the 3D structural data of UL89 inhibitors
with UL89-C.18 In our previous report, we found that pUL89-C
endonuclease activity was inhibited by the HIV inhibitor
raltegravir (1, Figure 1), suggesting that inhibiting pUL89-C is
possible using a similar metal-chelating pharmacophore.18
On the basis of computational molecular docking studies of 1
(Figure S2A), the pivotal chemical regions of 1 binding pUL89-
C endonuclease domain active site were identified. Upon
definition of the chemical features, a new set of compounds was
designed to improve the inhibition activity. Herein, we present
the synthesis and evaluation of a library of small organic
compounds able to inhibit UL89-C nuclease activity in an in
vitro enzymatic assay. The ability of these compounds to bind
UL89-C was tested by thermal denaturation. Furthermore, the
X-ray structure of a protein−ligand complex unveiled the precise
binding mode of the ligand in the enzyme active site, allowing a
further structure-driven antiviral development against UL89-C
activity.
■ RESULTS AND DISCUSSION
Rational Design and Chemistry. Our rational design
began by simplifying the structure of 1, a HIV integrase
inhibitor, by selecting chemical features important for UL89-C
binding. Computational docking studies of 1 in the active site of
UL89-C highlighted a number of molecular interactions that
contribute to binding affinity (Figure S2A). The pivotal regions
of 1 binding the pUL89-C active site are the metal chelator
group and the benzyl group. The three coplanar oxygen atoms of
the diketo acid (DKA) moiety chelate Mn2+ ions in the active
site, explaining the requirement for metal ions for drug binding.
The central oxygen, O(H), bridges both metal ions, whereas two
O (carbonyl) coordinates the metal ions (Figure S2A).
Additionally, the terminal phenyl ring interacts with Asn536
(distance = 3.74 Å), Met579 (3.30 Å), and Thr537 (4.66 Å).
These interactions could help position the inhibitor near the
divalent metal cations in the active site. The five-membered
oxadiazole moiety and isopropyl group are not directly involved
into interactions with the UL89-C binding site (distance
oxadiazole-Phe466 > 6.24 Å).
On this basis, we designed 2 containing an α,γ-DKA motif
linked to a 4-fluorophenyl ring (Figures 1 and 2A). The α,γ-
DKA core, a privileged structure found in thousands of HIV
integrase inhibitors with IC50 values in low micromolar
concentrations,38−45 is able to chelate Mn2+46 (Figure S2A)
and able to disrupt DNA−protein interactions.38,43,45,47−49 The
α,γ-DKAmotif has also been successfully used as a starting point
to obtain inhibitors against (1) hepatitis C virus NS5B
polymerase,50 (2) HIV-reverse transcriptase RNase H,51 (3)
hepatitis C virus NS5b polymerase,52 and (4) influenza
endonuclease.53 The 4-fluorophenyl ring is a common motif
found in 1 and other inhibitors.
Figure 1. Rational design of 14 as the UL89-C inhibitor.
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To validate our binding pose predictions and to facilitate
further structural modifications, we determined the crystal
structure of UL89-C bound with 2 (PDB code 6EY7). The
elucidation of the binding mode of 2 in the UL89-C binding site
by X-ray crystallography (see below and Figure 2A) and the
finding of 2 able to inhibit UL89-C prompted us to enlarge the
α,γ-DKA series (3−17, Schemes 1 and 2). The substituents on
the aromatic ring (3−4), amide (5), carboxylic acid (6−7), and
benzylic (8−17) positions were studied to determine SAR of the
series. The fluoride atom of 2 was substituted with iodine (3)
and bromine (4). In 5, the methyl group of the amide portion
was exchanged for a bulkier alkyl substituent. Furthermore, the
carboxylic functionality of 2 was converted to an amide (6−7).
The 4-fluorobenzyl and the N-methyl-4-fluorobenzylamine
groups of 2 were exchanged with a CH3 group to give 8 and
9, respectively. Different planar (hetero)aromatic rings,
variously decorated, have been added to the α,γ-DKA chelating
core (10−17) to promote a π−π stacking interaction with
Phe466.
On the basis of the remarkable profile shown by α,γ-DKA
derivatives, 18, lacking the α,γ-DKA core required to achieve
chelation, was used as the negative control. The synthesis of
compounds 2−5 and 8 was straightforward and was
accomplished in three reaction steps. In the first step, the
primary amine (2c−5c, Scheme 1) was acetylated under
standard conditions to afford the intermediate 2b−5b. The
preparation of intermediates 2a−5a was achieved by treating
2b−5b with dimethyl oxalate. Then, 2a−5a were hydrolyzed to
afford the corresponding acid derivatives (2−5).44,54,55
Compounds 6 and 7 were obtained by coupling methylamine
and 4-fluorobenzylamine, respectively, with 2. Compounds 8−9
and 13 were prepared by basic hydrolysis of 8a−9a and 13a
(Scheme 2).
Finally, on the basis of the structure of a potent HIV integrase
inhibitor MK-2048 (Figure S3A), we substituted the α,γ-DKA
core with a β,δ-DKA chelating group (19−20 and Figure S3A).
The synthesis of 19−20 (Scheme 3) started from the formation
of the dihydropyridone core (23), which was subsequently
ethylated giving 22 and then partially hydrolyzed obtaining
21.56−58 Afterward, 19b and 20b were obtained by coupling
benzylamines with 21, using amide coupling reagents. Finally,
ester derivatives 19b and 20b were converted to 19 and 20,
respectively.
UL89-C/2 Complex Structure. To study the binding mode
of 2, we determined the 3D crystal structure of the UL89-C/2
complex (PDB code 6EY7). Diffraction data collected from
crystals of UL89-C soaked with Mn2+ and 2 were solved by
molecular replacement, using the solved inhibitor-free UL89-C
Figure 2. Binding mode of 2 and 14 to UL89-C (A) X-ray crystal
structure of 2 (orange, PDB code: 6EY7) bound to UL89-C. Mn2+
atoms are shown as orange spheres. (B) Close-up view of the active site
in A. (C) Hydrogen-bonding network and hydrophobic interactions
between UL89-C, Mn2+, and 2 are depicted (mean distances shown in
Angstrom). (D) Docked conformation of 14 (iceblue) in the UL89-C
active site.
Scheme 1. Reagents and Conditions: (a) CH3NH2 or
C6H11NH2, Tetrahydrofuran (THF), Room Temperature
(rt), 12 h (35−40% Yield); (b) 2c−5c, CH3COCl, NEt3,
CH2Cl2, 0 °C, 2 h (82−99%); (c) LiHMDS, THF,−78 °C, 0.5
h, Then (CH3OCO)2, 0 °C, 4 h (38−95%); (d) LiOH 1 N,
MeOH, 40 °C, 2 h (49−100%); and (e) Amine, HBTU,DIEA,
Dimethylformamide (DMF), rt, Overnight (26−44%)
Scheme 2. Reagents and Conditions: (a) LiOH 1 N, MeOH,
40 °C, 1 h (69−79% Yield)
Scheme 3. Reagents and Conditions: (a) HC(OEt)3,
CO(NH2)2, Refluxing Xylenes, 4 h (57% Yield); (b) 23, EtBr,
K2CO3, DMF, 80 °C, 14 h (34%); (c) 22 (1 equiv), KOH (1
equiv), EtOH, rt, Overnight (65%); (d) 21, N-(4-
Fluorobenzyl)-N-metilamine or N-4-Fluorobenzylamine,
EDCI, HOAt, DCM, rt, Overnight (35−36%); and (e) LiOH
1 N, MeOH, 40 °C, 1 h (43−97%)
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as the initial model.18 Strong electron density within the active
site was observed adjacent to the Mn2+ ions (Figure S2B).
The UL89-C/2 structure was refined to 2.9 Å resolution
(Table 2). The UL89-C/2 crystal also showed anomalous
scattering, confirming the presence of two Mn2+ ions in the
active site. As expected, 2 bound through the α,γ-DKA core to
the two Mn2+ ions in the active site (Figure 2B). The three
adjacent oxygen atoms of the α,γ-DKA fragment chelated the
two Mn2+ ions in a pairwise fashion such that the central oxygen
atom was bridging the two ions (Figure 2B). Thus, the Mn2+
ions were coordinated by two acidic residues (Glu534-Asp463
or Asp463-Asp651) from UL89-C and two oxygen atoms of 2
(Figure 2B) in a tetrahedral geometry. An identical coordination
pattern has been observed between the active site of LACV L-
protein and an α,γ-DKA derivative.59 All four compounds in the
asymmetric unit of the UL89-C/2 crystals showed clear electron
density for the orientation displayed in Figure 2A. The complex
UL89-C/2 also revealed that the 4-fluorobenzyl group blocks a
region crucial for DNA/UL89-C recognition. To further
confirm the presence of 2 in the UL89-C/2 complex, we
exchanged the fluorine atom for iodine (3) or bromine (4) atom
because both are able to originate measurable anomalous
scattering effects. Indeed, the anomalous difference maps
confirmed the presence of the iodine atom of 3 in the UL89-
C/3 complex (Table 2). The position of the iodine atom on the
UL89-C/3 complex overlaps with the fluorine atom of 2 found
in UL89-C/2 (Figure S2C). On the basis of the crystallographic
studies on UL89-C/2 and UL89-C/3, the α,γ-DKA chelating
core served as the metal-binding motif and the 4-fluorophenyl
ring afforded additional interactions with the hydrophobic cleft
formed by Asn536 and Met579 (Figure 2B,C). The methyl
group of 2, pointing outside the binding site, may be substituted
with a bulky alkyl group to get an additional hydrophobic
interaction with the close Phe466 (Figure 2B,C). The carboxylic
acid interacted with Ser473 by hydrogen bonds with a distance
of 3.6 Å (Figure 2C).
Inhibition of UL89-C Nuclease Activity. A quantitative
UL89-C nuclease assay was designed to evaluate the inhibition
potency of 1−20. These compounds passed through a pan assay
interference compounds filter (http://zinc15.docking.org/
patterns/home/).60
Linear DNA and UL89-C were incubated at 37 °C for 30 min
in the presence of 1−20 at a concentration of 50 μM. Linear
DNA was run on an agarose gel electrophoresis gel, stained with
Syto 60, and quantified by fluorescence analysis. The
compounds revealed a percentage of inhibition ranging from
totally inactive (0%) to almost complete inhibition (97%)
(Table 1). At 50 μM, 1 and 2 showed similar inhibition (36.6
and 56.2%) but with an improvement of the percentage
efficiency index (PEI) (defined as the percentage of inhibition
at a given concentration/molecular weight) from 0.08 to 0.15
because of the lower molecular weight of 2 (Figure 1).
Using a novel enzyme-linked inmunosorbent assay format as a
screening assay, Wang et al. found that 1 inhibited pUL89-C
activity with a IC50 of 96 μM. These results are in a good
agreement with the inhibitory response in our assay.34
The comparable activity of 1 and 2 corroborated our
hypothesis that an α,γ-DKA scaffold linked to a 4-fluorophenyl
group was the minimum motif required to modulate the UL89-
C nuclease activity. We studied the importance of each
individual group, α,γ-DKA and 4-fluorophenyl, in the
contribution to the inhibition of the activity of UL89C by
analyzing the activity of both fragments separately, 2b and 8
(Figure S3B), and we confirmed our hypothesis that they were
unable to inhibit UL89-C activity (Table 1).
On the basis of the UL89-C/2 complex structure, several α,γ-
DKA compounds decorated with different (hetero)aromatic
groups spanning a wide range of size, aromaticity, and H-bond
capability (3−17) were selected for further studies. The
substitution of the fluorine atom of 2 for iodine (3) or bromine
(4) slightly improved the activity (47.7 and 51.5%, respectively).
The substitution of the methyl group of 2 for a cyclopropyl ring
(5) showed an improvement of potency from 37.4 to 76.3%. The
Table 1. In Vitro Activities of 1−20 Against UL89-C
compound % inhibition at 50.0 μM % inhibition at 25.0 μM % inhibition at 12.5 μM % inhibition at 6.25 μM % inhibition at 3.12 μM
1 36.6 ± 7.1a 22.1 ± 10.6
2 56.2 ± 4.9 20.3 ± 7.1
2b n.a.b
3 47.7 ± 7.1 26.8 ± 7.1
4 51.5 ± 7.8 10.7 ± 8.5





10 62.6 ± 12.0 46.6 ± 4.2 29.7 ± 3.5
11 26.8 ± 4.2 3.6 ± 2.8
12 89.1 ± 5.7 47.6 ± 0.4 32.7 ± 0.7
13 42.6 ± 6.4 15.4 ± 7.1
14 97.2 ± 5.0 90.6 ± 3.5 65.0 ± 2.8 45.8 ± 7.1 12.5 ± 2.8
15 75.6 ± 1.4 33.3 ± 14.1 1.1 ± 0.7
16 66.7 ± 1.4 52.0 ± 3.5 28.2 ± 0.9




aMean and SD of three experiment. bn.a. = not active.
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improved activity of 5 might be related to the additional
interaction between the cyclopropyl fragment and Phe466.
Derivatization of the carboxylic acid functionality to an amide (6
and 7) led to inactive compounds, confirming the crucial role of
the electrostatic interaction between the carboxyl group with
Mn2+. The replacement of the aromatic ring of 2 with a methyl
(8 and 9, Scheme 2) resulted in a complete loss of activity as
well, pointing to a possible role for the aromatic substituent in
the recognition process. Altogether, these preliminary results
suggested that an α,γ-DKA scaffold linked to a bulky aromatic
substituent might contribute to UL89-C inhibition. Starting
from this assumption, we were keen to examine the effects of
different (hetero)aromatic substituents on the α,γ-DKA system.
To this end, derivatives 10−17 (Scheme 2) were assayed.
Derivatives bearing an electron-rich aromatic ring such as 4-
methylphenyl (12), phenylpiperidine (14), or a heteroaromatic
ring (17) exhibited high inhibitory activity (89.1−97.2%).
Instead α,γ-DKA compounds bearing an electron-deficient
aromatic ring such as a 4-fluorophenyl (11), 4-trifluoromethyl-
phenyl (13), or 4-pyridyl (15) showed low inhibition at 50.0
μM. Structural changes introduced in the metal-chelating motif,
as in 18, greatly affected the ability of the inhibitor to bind to the
active site. On top of that, the alteration of the α,γ-DKA
chelating core by an α,δ-DKA (19 and 20)made the compounds
unable to chelate the metal ions in the active site.
To estimate the IC50 values, the concentrations of 1-5, 10, 12,
and 14−17 were lowered to 25, 12.5, 6.2, and 3.1 μM,
respectively, in the fluorescent UL89-C nuclease assay. At a
lower concentration (25 μM), 1−4 showed low activity,
meanwhile compound 5, bearing a cyclopropyl group on
nitrogen atom, showed the highest activity between derivatives
1−5; this might be due to an additional hydrophobic interaction
with Phe466. To note, the halogen atom (fluorine, iodine, or
bromine) attached to the phenyl group (2−4) does influence
the inhibitory potency of α,γ-DKA compounds to UL89-C.
Among 10−17, we observed that α,γ-DKA compounds bearing
a pyridine ring (15), a 4-fluorobenzene (11), or a 4-
trifluoromethyl-benzene (13) have low inhibitory activity
against UL89-C. This might be due to the substituent effect
on the electrostatic potential of the benzene ring. A strong
dependence on the electrostatic potential of the aromatic ring
and UL89-C affinity is suggested. Compounds bearing a
benzene ring decorated with substituents such as CF3 or F
have shown to be less potent than compounds bearing electron-
donating groups such as NR2 or CH.
61,62 As expected, lowering
further the concentration to 12.5 and 6.25 μM, 5, 10, 12, and 16
showed a reduced percentage of inhibition (22.6−32.7%, Table
1), whereas 14 and 17 still showed good potency against UL89-
C (65 and 80%, respectively). The estimated IC50 values for 14
and 17 are 4.5 and 9.2 μM, respectively (Figure S4A,B).
Furthermore, 14 showed a PEI of 0.35, four times greater than
that of 1 (PEI = 0.08, Figure 1). The high activity of 14might be
due, as predicted by docking simulation, to a strong π−π
interaction between Phe466 and the electron-rich aromatic ring
of 14 (Figure 2D). From the focused library of α,γ-DKA, we
identified that the minimal structural determinant for the UL89-
C activity is an α,γ-DKA group linked to an electron-rich
aromatic ring (Figure S15).
Thermal Shift Assay. Protein melting temperature (Tm)
determined by thermal shift assays (TSAs) is used to monitor
ligand effects on protein stability.63 The interaction of a ligand
with the protein usually causes an increase in Tm. TSA was used
to study the thermal stabilization of UL89-C upon binding of 14,
17, and 18, and the latter was used as a negative control (Figure
3). Tm of ligand-free UL89-C was 52.7 °C (in the presence of
dimethyl sulfoxide (DMSO), Tm was 52.0 °C). A significant rise
in Tm was observed for 14 (Tm = 55.7 °C) and 17 (Tm = 55.5
°C), confirming their ability to bind UL89-C and stabilizing the
protein. 18 did not stabilize the protein (Tm = 52.5 °C, Figure 3),
thus confirming lack of binding to UL89-C. These results further
suggested that the α,γ-DKA core was a crucial motif required for
UL89-C inhibition.
Docking. Molecular docking studies were conducted to
elucidate the binding mode of UL89-C inhibitors in the active
site for the noncrystallized complexes. The atomic coordinates
of the UL89-C active site were used for computational docking
of 1, 2, 14, and 17 (Figures S2A, 2D, and S2D). The binding
pose of 1 showed that (i) the chelating motif was positioned
close to the twoMn2+ cations, (ii) the 4-fluorobenzyl substituent
interacted by hydrophobic interaction with Asn536 andMet579,
and (iii) the oxadiazole fragment is not directly involved in the
interactions with the UL89-C binding site. The predicted
binding pose of 2 showed the same orientation of groups i and ii
as 1. The root-mean-square deviation (rmsd) between the
docked and crystallographic poses of 2 on the UL89-C active site
is 0.9 Å. Molecular docking simulation of 14 and 17
demonstrated that the α,γ-DKA group chelated the two Mn2+
cations and the electron-rich aromatic ring interacted with the
adjacent Phe466 by π−π interaction (Figures 2D and S2D).
■ CONCLUSIONS
UL89 HCMV terminase is a promising antiviral target because
of its key role in the processing and packaging of the viral DNA
inside the capsid, during viral replication. Blocking this crucial
step could avoid the spread of the infection.We have focused our
efforts on developing potential inhibitors against UL89-C
because its nuclease activity is exclusive to the virus. On the
basis of the structure of 1, a weak inhibitor of UL89-C, we
designed 2. Compound 2, bearing an α,γ-DKA scaffold linked to
a 4-fluorophenyl group, is able to inhibit UL89-C activity. Here,
we report the X-ray structure of UL89-C bound to two α,γ-DKA
derivatives (2 and 3) as well as the in vitro thermal shift and
nuclease assays. Our studies showed that the alterations of the
α,γ-DKA scaffold proved to be deleterious to the activity and the
Figure 3. Thermal stability measured by TSA experiments of UL89-C/
Mn2+ in the absence and presence of 14, 17, and 18 at 25 μM inDMSO.
18 was used as the negative control. Values are the mean ± standard
deviation (SD) (n = 3).
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potency was influenced by substituents on the α,γ-DKA core.
Among them, 14, bearing an α,γ-DKA group linked to an
aromatic electron-rich moiety, inhibited UL89-C at low
micromolar range. The molecular binding of 14 to UL89-C
was confirmed by a fluorescence-based thermal stability assay
and its binding interactions were predicted by molecular
docking simulation. Considering the strong correlation found
with UL89 inhibitors against UL89 enzyme and antiviral
potency,34,35 14 is an optimal candidate to be tested in
HCMV-infected cells. Moreover, several DKA derivatives have
exhibited low cytotoxicity in vitro64−69 so we expect that 14
would share this feature in vitro as well. The structural
information gained from the UL89-C/2 complex and the
identification of the chemical features determining the UL89-C
inhibition will allow further development and optimization of
α,γ-DKA inhibitors against the HCMV UL89-C.
■ EXPERIMENTAL SECTION
Synthesis of Inhibitors. Synthetic and chemical character-
ization for all compounds can be found in the Supporting
Information General Chemistry Materials and Methods section.
X-ray Crystallography. UL89-C was purified and crystal-
lized as previously described.18 Crystals of UL89-C were grown
by mixing the protein solution with a solution containing 10%
Mes 1 M pH 6.5, 6% PEG8000, and 150 mM calcium acetate in
sitting drop plates at 20 °C for 1 week. The crystal complex
between the UL89-C and the inhibitor was formed by soaking
the protein crystals in a solution containing 1 mM of 2 or 3, 2
mM of MnCl2, 10% Mes 1 M, 6% PEG8000, and 150 mM
calcium acetate. 2was soaked for one week, and 3was soaked for
24 h. All crystals were cryoprotected in reservoir buffer
containing 1 mM of 2 in 10% PEG400 or 3 in 20% glycerol
and flash-cooled in liquid nitrogen prior to diffraction analysis.
Diffraction data were recorded from cryocooled crystals (100 K)
at the ALBA synchrotron in Barcelona (BL13-XALOC beam-
line). Data were integrated and merged using XDS70 and scaled
using XSCALE.71 The structure of the complexes was solved by
molecular replacement with the CCP4 supported program
MOLREP72,73 using theUL89-C structure (PDB code 3N4P) as
a starting model and refined with Refmac74 and manually
checked with Coot.75 2 was placed (LigandFit, PHENIX
supported program)76 and refined (phenix.refine, PHENIX
supported program)77 in the additional electron density present
at the active site pocket. For the UL89-C/3 complex, anomalous
data were collected at wavelength 0.9194 Å and the difference
anomalous map was calculated (Figure S2C). Molecular
topologies for 2 and 3 were generated with PRODRG server.78
Data collection and refinement statistics are shown in Table 2.
In Vitro Nuclease Assay. Purified UL89-C at a concen-
tration of 3 μM dissolved in a buffer containing 30 mM Tris pH
8.0 and 50 mMNaCl was mixed with 3 mMMnCl2 and different
concentrations of inhibitors 1−20 (50−3.2 μM) in DMSO. The
concentration of DMSO was 5% in all reactions. The nuclease
activity was started by addition of 100 ng of linear pOPINM
vector, digested with KpnI−HindIII. The reaction was
incubated for 30 min at 37 °C. After that time, the reaction
was stopped by addition of ethylenediaminetetraacetic acid at a
final concentration of 30 mM. Then, 0.2 μMof Syto 60 stain in a
dye-free loading buffer was added. The samples were incubated
for 10 min and loaded on an agarose gel (1%). Gel
electrophoresis was run at 90 V for 45 min in the dark in 1×
TAE buffer. The image of the agarose gel was obtained from the
LI-COR Odyssey Infrared Imaging equipment. The non-
digested DNA in the reaction was quantified using Odyssey
Infrared Imaging system version 3.0 software, using a control
DNA for the measurements. The percentage of inhibition was
obtained from the amount of DNA present at different
concentrations of inhibitors.
Thermal Shift Assay.The aliquots were prepared on ice in a
96-well polymerase chain reaction (PCR) plate (Bio-Rad)
sealed with optically clear PCR sealers (Bio-Rad) and contained
15 μM UL89-C, 30 mM Tris-HCl (pH 8.0), 50 mM NaCl,
Sypro Orange protein (Invitrogen), and 0.5 mM MnCl2. Then,
14, 17, and 18 dissolved in DMSO were added at a final
concentration of 25 μM. For the control, the same volume of
DMSO was added to reach a final concentration of 5%. The
samples were heated from 20 to 95 °C at a rate of 0.5 °C/min,
and the change in fluorescence (λex = 490 nm; λem = 575 nm)
was monitored over time in an iCycler iQ Real Time PCR
Detection system (Bio-Rad). All measurements were carried out
in triplicate. Data evaluation and melting point determination
were performed using Bio-Rad Optical System Software.
Computational Docking Studies. The 3D structures of 1,
2, 14, and 17 were docked to the crystal structure of UL89-C
Table 2. Data Collection and Refinement Statisticsa
2-Mn2+-UL89-C 3-Mn2+-UL89-C
Data Collection
wavelength (Å) 1.240 1.9997
space group P212121 P212121
Unit Cell Dimensions
a, b, c (Å) 81.6, 87.6, 186.6 81.3, 87.2, 185.3





completeness (%) 98.8 (99.7) 99.6 (100.0)
CC1/2 99.8 (65.4) 99.8 (82.5)
multiplicity 5.2 (5.6) 6.4 (6.7)
R-meanb (%) 8.0 (103.0) 13.5 (107.3)
I/sigma 14.4 (1.8) 10.35 (1.79)
no. of unique reflections
refinement


















rmsd Deviation from Ideal Values
rmsd bond lengths (Å) 0.009
rmsd bond angles (deg) 1.105
aStatistic for the highest resolution shells shown in parentheses. bRmeas
= [Σh(nh/[nh − 1])1/2Σi|Iĥ − Ih,i|]/ΣhΣiIh,I, where Iĥ = (1/nh) ΣiIh,I and
nh is the number of times a reflection is measured.
cRwork = Σhkl||Fobs| −
k|Fcalc||/Σhkl|Fobs|. dRfree = Σhkl⊂T||Fobs| − k|Fcalc||/Σhkl⊂T|Fobs| where T
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(PDB code: 3N4P) using AutoDock v4.2 (Molecular Graphics
Lab., The Scripps Research Institute, La Jolla, CA, USA)
available at http://autodock.scripps.edu. The 3D structures of 1,
2, 14, 17, and UL89-C (PDB code: 3N4P) were first converted
from pdb into pdbqt format using MGL Tools. Gesteiger partial
charges were used for both the enzyme and ligands. The active
site was defined as a grid box centered at the −23.00, 26.75, and
−4.94 coordinates with 0.4 Å units in the x, y, and z directions to
cover the entire binding site. 1, 2, 14, and 17 were docked
flexibly into the active site of the UL89-C structure. Docking
simulations were performed with the following parameters:
number of energy evaluations (2 500 000), genetic algorithm
runs (100), and population size (150).79 The representative
pose of the most populated cluster was selected.
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